Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Chemotherapy in Early TNBC (GeparDouze)
NCT03281954Phase 3Active, not recruiting
- Sponsor
- NSABP Foundation
- Start
- Dec 2017
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by NSABP Foundation. Started Dec 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03281954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281954.